Bone Health and Denosumab Discontinuation in Oncology Populations

被引：2
|
作者：
Cheung, Yee-Ming Melody [1 ,2 ,3 ]
Morgans, Alicia [2 ,4 ]
Hamnvik, Ole-Petter Riksfjord [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave,RFB 2, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Melbourne, Austin Hosp, Dept Med, Endocrine Unit, Melbourne, Vic, Australia
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
ONCOLOGIST | 2022年 / 27卷 / 12期
关键词：
bone health; cancer; denosumab discontinuation; multiple vertebral fractures; rebound phenomenon; ZOLEDRONIC ACID; MINERAL DENSITY; BREAST-CANCER; VERTEBRAL FRACTURES; PROSTATE-CANCER; DOUBLE-BLIND; POSITION STATEMENT; METASTASES; PREVENTION; THERAPY;
D O I：
10.1093/oncolo/oyac213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Managing bone health after denosumab cessation is a commonly encountered challenge. Although the "rebound phenomenon" is generally recognized by endocrinologists in the context of osteoporosis, it is not as widely understood in the context of bone metastases and cancer. This commentary reviews the evidence on the efficacy and safety of various bone health agents in mitigating the "rebound phenomenon" in cancer populations.
引用
收藏
页码：998 / 1003
页数：6
相关论文
共 50 条
  • [21] Palliative Oncology: Denosumab
    Prommer, Eric
    AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2015, 32 (05): : 568 - 572
  • [22] Critical Hypercalcemia Following Discontinuation of Denosumab Therapy for Metastatic Giant Cell Tumor of Bone
    Gossai, Nathan
    Hilgers, Megan V.
    Polgreen, Lynda E.
    Greengard, Emily G.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (06) : 1078 - 1080
  • [23] Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density Reduction
    Lee, Chia-Che
    Wang, Chen-Yu
    Yen, Hung-Kuan
    Hung, Chih-Chien
    Lai, Cheng-Yo
    Hu, Ming-Hsiao
    Wang, Ting-Ming
    Li, Chung-Yi
    Fu, Shau-Huai
    JAMA NETWORK OPEN, 2024, 7 (11)
  • [24] Mechanisms to explain the overshoot in bone remodeling markers after denosumab discontinuation: are we there yet?
    Ramchand, Sabashini K.
    Mcdonald, Michelle M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2025, 40 (03) : 299 - 300
  • [25] Use of bisphosphonates to prevent bone loss with denosumab discontinuation: observations from clinical practice
    Duge, Leanne
    Dickens, Laura Thomason
    Jain, Rajesh
    Vokes, Tamara J.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 : 160 - 160
  • [26] Certainties and Uncertainties About Denosumab Discontinuation
    Tsourdi, Elena
    Zillikens, M. Carola
    CALCIFIED TISSUE INTERNATIONAL, 2018, 103 (01) : 1 - 4
  • [27] Certainties and Uncertainties About Denosumab Discontinuation
    Elena Tsourdi
    M. Carola Zillikens
    Calcified Tissue International, 2018, 103 : 1 - 4
  • [28] Discontinuation of denosumab in men with prostate cancer
    Anne Sophie Sølling
    Torben Harsløf
    Helle Kongsbak Brockstedt
    Bente Langdahl
    Osteoporosis International, 2023, 34 : 291 - 297
  • [29] Bisphosphonates or denosumab discontinuation and risk of fractures
    Anastasilakis, Athanasios D.
    Yavropoulou, Maria P.
    Makras, Polyzois
    MATURITAS, 2017, 102 : 75 - 75
  • [30] Discontinuation of denosumab in men with prostate cancer
    Solling, Anne Sophie
    Harslof, Torben
    Brockstedt, Helle Kongsbak
    Langdahl, Bente
    OSTEOPOROSIS INTERNATIONAL, 2023, 34 (02) : 291 - 297
12345